RAPT
RAPT
NASDAQ · Biotechnology

Rapt Therapeutics Inc

$58.02
+0.04 (+0.07%)
As of Mar 22, 10:07 PM ET ·
Financial Highlights (FY 2025)
Revenue
545.80M
Net Income
29.97M
Gross Margin
45.4%
Profit Margin
5.5%
Rev Growth
+0.6%
D/E Ratio
0.27
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 45.4% 45.4% 45.4%
Operating Margin 5.4% 5.5% 6.0%
Profit Margin 5.5% 5.9% 4.8%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 545.80M 533.51M 481.00M
Gross Profit 247.62M 242.05M 218.22M
Operating Income 29.67M 29.47M 28.92M
Net Income 29.97M 31.31M 23.12M
Gross Margin 45.4% 45.4% 45.4%
Operating Margin 5.4% 5.5% 6.0%
Profit Margin 5.5% 5.9% 4.8%
Rev Growth +0.6% -0.7% +10.6%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 213.02M 239.98M 188.05M
Total Equity 779.98M 712.25M 723.38M
D/E Ratio 0.27 0.34 0.26
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 42.09M 36.52M 35.99M
Free Cash Flow 24.22M 23.20M 21.80M